Publications by authors named "Matthews Maruva"
Article Synopsis
- In 2010, WHO updated guidelines aimed at preventing mother-to-child transmission of HIV, prompting a study on their effectiveness in Zimbabwe.
- Using a computer model, researchers simulated different PMTCT treatment options for HIV-positive pregnant women and analyzed the resulting life expectancy and healthcare costs.
- Findings showed that newer treatment options (Options A, B, and B+) not only improved health outcomes for mothers and infants but also reduced long-term costs compared to the older sdNVP regimen, with Option B+ offering the best health benefits for a reasonable cost.
Background: The World Health Organization (WHO) has called for the "virtual elimination" of pediatric HIV: a mother-to-child HIV transmission (MTCT) risk of less than 5%. We investigated uptake of prevention of MTCT (PMTCT) services, infant feeding recommendations, and specific drug regimens necessary to achieve this goal in Zimbabwe.
Methods And Findings: We used a computer model to simulate a cohort of HIV-infected, pregnant/breastfeeding women (mean age, 24 y; mean CD4, 451/µl; breastfeeding duration, 12 mo).
Background: The Zimbabwean national prevention of mother-to-child HIV transmission (PMTCT) program provided primarily single-dose nevirapine (sdNVP) from 2002-2009 and is currently replacing sdNVP with more effective antiretroviral (ARV) regimens.
Methods: Published HIV and PMTCT models, with local trial and programmatic data, were used to simulate a cohort of HIV-infected, pregnant/breastfeeding women in Zimbabwe (mean age 24.0 years, mean CD4 451 cells/µL).